|
|
|
Compugen LTD (Israel - Coordinator)
Ms Zipi (Fligelman) Shaqed
Compugen is a biotechnology discovery company focused on therapeutic and diagnostic products. The Company's powerful predictive models and discovery engines enable the discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's pioneering and on-going incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's discovery efforts have focused mainly on cancer, cardiovascular and immune-related diseases. Product development is pursued both in-house and through collaborative arrangements. The Company's primary business goal is to out-license therapeutic and diagnostic product candidates for commercialization by leading companies under milestone and revenue sharing agreements. Compugen has established an agricultural biotechnology affiliate - Evogene, and a small-molecule drug discovery affiliate - Keddem Bioscience.
|
ARTTIC Israel (Israel)
Mr Arnon Rund
Founded in 1987, ARTTIC is the leading European group providing consultancy and management services to international technology-related partnerships. ARTTIC is highly specialized and provides exclusively services related to the set-up and management of European R&D collaborations, and only in the specific sectors where its consultants have valuable expertise: IT, telecommunications, transports, education, health, bio-technologies, automotive industry, aeronautics, industrial technologies, new materials and microelectronics.
|
Aureus Pharma (France)
Dr Jason Theodosiou
Aureus Pharma designs, develops and markets a novel integrated knowledge management platform which combines computerized knowledge management system with experimental assay data mined from the scientific literature. By bringing together information pertaining to the relationships between protein targets, biological function and ligands within one single system, Aureus helps researchers transform data into knowledge to accelerate the drug discovery process.
|
Consejo Superior de Investigaciones Científicas (Spain)
Dr Piero Crespo
The Instituto de Investigaciones Biomédicas (IIB) is a center within the Consejo Superior de Investigaciones Científicas (Spanish Research Council) internationally recognized as a center of excellence in basic oncology research, in particular in areas concerning signal transduction. The IIB Biomedicine Unit, is an extramural unit associated to the Faculty of Medicine of the University of Cantabria (Santander, Spain), in which staff from both the CSIC and the University of Cantabria work in close collaboration in basic and translational research within an environment in which a close contact with the clinics provides optimal conditions.
|
Institut De Recerca Hospital Universitari Vall De Hebron (Spain)
Prof Jose Baselga
Vall d’Hebron is the largest university hospital in Spain with a comprehensive cancer center with both a basic and a clinical research program incorporating translational endpoints. Our cancer clinic serves a population of 1,5 million with a total of 800 hundred and 400 hundred new patients per year with breast and colorectal cancer, respectively. The clinical research program is basically dedicated to breast, non-small cell lung and gastrointestinal cancer patients. One of the primary objectives of this translational research program is devoted to the identification of new preclinical and clinical pharmacodynamic endpoints with molecular targeted therapies and subsequently incorporates them in the clinical trials.
|
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori (Italy)
Prof Marco Pierotti
The Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan, Italy, is an internationally renewed Comprehensive Cancer Center, with a staff of 1,300 people, including preclinical and clinical investigators, technicians, nurses, auxiliaries, and administrative personnel. About 450 beds are available for hospitalization at INT, and 13,000 new patients are hospitalized each year and 14,600 are submitted to diagnostic or treatment procedures in the Day Hospital of the Outpatient Clinic (detailed information about clinical and preclinical activity at the INT is available at the INT website: http://www.istitutotumori.mi.it). The mission of the Institute is to carry out research on prevention, diagnosis and treatment of malignant and pre-malignant diseases based on the joint activity of preclinical and clinical scientists to challenge cancer from different perspectives. At present, 100 clinical mono-centric and multi-centric research protocols (all of them approved by an independent Ethical Committee) are active, including those of gene therapy recently activated for patient with cutaneous melanoma or lung cancer.
|
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. (Germany)
Prof Thomas Meyer
The Max Planck Society for the Advancement of Science is an independent, non-profit research organization that primarily promotes and supports research at its own institutes. The Max Planck Institute for Infection Biology (MPI-IB) employs multi-disciplinary approaches to infection biology, comprising concepts and methodologies of molecular genetics, immunology, cell biology, epidemiology, clinical research and protein chemistry. The Institute promotes the applications of new technologies such as RNA interference towards paving the way for the genome wide gene function analysis and its development as a therapeutic tool.
|
The University of Glasgow (United Kingdom)
Prof David Gilbert
The University of Glasgow is one of the United Kingdom's largest, oldest and most prestigious universities, with an international reputation for its research and an important role in the commercial life of the country. The University has one of the largest research bases in the UK with over 3,400 researchers, Europe's largest collection of life scientists working in the Institute of Biomedical & Life Sciences and one of the largest medical schools in Europe.
|
Weizmann Institute of Science (Israel)
Prof Rony Seger
Prof Yossi Yarden
The Weizmann Institute of Science, is one of the top-ranking multidisciplinary research institutions in the world. Noted for its wide-ranging exploration of the sciences and technology, the institute gathers together 2,500 scientists, technicians and research students devoted to adventuring into the unknown. At the Weizmann Institute, several dozen research teams are attacking the problem of cancer in different directions; their studies are conducted within the framework of several research centers whose activities are coordinated by Weizmann’s M.D. Moross Institute for Cancer Research. Two of these research teams are represented in the SIMAP project.
|
|
